107 related articles for article (PubMed ID: 18089933)
1. Serum levels of pigmentation markers are elevated in patients undergoing hemodialysis.
Murakami K; Wakamatsu K; Nakanishi Y; Takahashi H; Sugiyama S; Ito S
Blood Purif; 2007; 25(5-6):483-9. PubMed ID: 18089933
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of 5-s-cysteinyldopa are correlated with skin colors in hemodialysis patients but not in peritoneal dialysis patients.
Murakami K; Nakanishi Y; Wakamatsu K; Yamamoto K; Kohriyama N; Hasegawa M; Tomita M; Nabeshima K; Hiki Y; Asano S; Kawashima S; Ito Y; Fujita Y; Asada H; Nakai S; Sugiyama S; Ito S
Blood Purif; 2009; 28(3):209-15. PubMed ID: 19648740
[TBL] [Abstract][Full Text] [Related]
3. Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis.
Lobo J; Santos F; Grosso D; Lima R; Barreira AL; Leite M; Mafra D; Abdalla DS
Nephron Clin Pract; 2008; 108(4):c298-304. PubMed ID: 18434752
[TBL] [Abstract][Full Text] [Related]
4. Increased whole blood chemiluminescence in patients with chronic renal failure independent of hemodialysis treatment.
Rysz J; Potargowicz E; Banach M; Luczyńska M; Stolarek R; Białasiewicz P; Kasielski M; Ciałkowska-Rysz A; Nowak D
Arch Immunol Ther Exp (Warsz); 2006; 54(5):347-55. PubMed ID: 17031465
[TBL] [Abstract][Full Text] [Related]
5. Increased levels of serum matrix metalloproteinase-3 in haemodialysis patients with dialysis-related amyloidosis.
Naganuma T; Sugimura K; Uchida J; Tashiro K; Yoshimura R; Takemoto Y; Nakatani T
Nephrology (Carlton); 2008 Apr; 13(2):104-8. PubMed ID: 18275497
[TBL] [Abstract][Full Text] [Related]
6. Serum non-transferrin bound iron in hemodialysis patients not receiving intravenous iron.
Prakash M; Upadhya S; Prabhu R
Clin Chim Acta; 2005 Oct; 360(1-2):194-8. PubMed ID: 15979061
[TBL] [Abstract][Full Text] [Related]
7. Th1 polarization and low-T3 syndrome are correlated with hyperleptinemia in hemodialysis patients.
Liu ML; Huang ZY; Zhong XC; Liu SH; Xu G; Jiang TY; Xi WW; Yan WQ
J Nephrol; 2009; 22(4):515-22. PubMed ID: 19662608
[TBL] [Abstract][Full Text] [Related]
8. Relationship of serum cystatin C with C-reactive protein and apolipoprotein A1 in patients on hemodialysis.
Samouilidou EC; Grapsa E
Ren Fail; 2008; 30(7):711-5. PubMed ID: 18704820
[TBL] [Abstract][Full Text] [Related]
9. Oxidative stress in elderly chronic renal failure patients: effects of renal replacement therapies on cell membrane fluidity.
Goi G; Massaccesi L; Baquero Herrera CJ; Musetti C; Ciurlino D; Cusi D; Bertoli S
J Nephrol; 2009; 22(5):630-6. PubMed ID: 19809996
[TBL] [Abstract][Full Text] [Related]
10. Cardiac findings in asymptomatic chronic hemodialysis patients with persistently elevated cardiac troponin I levels.
Katerinis I; Nguyen QV; Magnin JL; Descombes E
Ren Fail; 2008; 30(4):357-62. PubMed ID: 18569907
[TBL] [Abstract][Full Text] [Related]
11. Assessment of inflammatory factors and cardiac troponin T in hemodialysis patients.
Falaknazi K; Bagheri N; Taziki O
Saudi J Kidney Dis Transpl; 2009 Mar; 20(2):219-22. PubMed ID: 19237807
[TBL] [Abstract][Full Text] [Related]
12. Serum protein-bound 3,4-dihydroxyphenylalanine and related products of protein oxidation and chronic hemodialysis.
Sutherland WH; Gieseg SP; Walker RJ; de Jong SA; Firth CA; Scott N
Ren Fail; 2003 Nov; 25(6):997-1009. PubMed ID: 14669859
[TBL] [Abstract][Full Text] [Related]
13. A circulating beta 2-microglobulin intermediate in hemodialysis patients.
Uji Y; Motomiya Y; Ando Y
Nephron Clin Pract; 2009; 111(3):c173-81. PubMed ID: 19194107
[TBL] [Abstract][Full Text] [Related]
14. Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients.
Costa E; Pereira BJ; Rocha-Pereira P; Rocha S; Reis F; Castro E; Teixeira F; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
Am J Nephrol; 2008; 28(4):677-83. PubMed ID: 18354252
[TBL] [Abstract][Full Text] [Related]
15. Elevated hepatocyte growth factor levels at the beginning of high-flux hemodialysis are due to heparin administration.
Christidou F; Bamichas G; Galaktidou G; Fragidis S; Gionanlis L; Frangia T; Bischiniotis T; Sombolos K
Ren Fail; 2008; 30(9):861-4. PubMed ID: 18925524
[TBL] [Abstract][Full Text] [Related]
16. Human erythrocyte delta-aminolevulinate dehydratase activity and oxidative stress in hemodialysis patients.
Valentini J; Schmitt GC; Grotto D; Santa Maria LD; Boeira SP; Piva SJ; Brucker N; Bohrer D; Pomblum VJ; Emanuelli T; Garcia SC
Clin Biochem; 2007 Jun; 40(9-10):591-4. PubMed ID: 17462617
[TBL] [Abstract][Full Text] [Related]
17. The effect of on-line high-flux hemofiltration versus low-flux hemodialysis on mortality in chronic kidney failure: a small randomized controlled trial.
Santoro A; Mancini E; Bolzani R; Boggi R; Cagnoli L; Francioso A; Fusaroli M; Piazza V; Rapanà R; Strippoli GF
Am J Kidney Dis; 2008 Sep; 52(3):507-18. PubMed ID: 18617304
[TBL] [Abstract][Full Text] [Related]
18. Angiopoietin 2 and cardiovascular disease in dialysis and kidney transplantation.
David S; Kümpers P; Hellpap J; Horn R; Leitolf H; Haller H; Kielstein JT
Am J Kidney Dis; 2009 May; 53(5):770-8. PubMed ID: 19268412
[TBL] [Abstract][Full Text] [Related]
19. Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa.
Stewart RM; Miller S; Gunder M
Acta Derm Venereol; 1983; 63(2):97-101. PubMed ID: 6189350
[TBL] [Abstract][Full Text] [Related]
20. Markers of endothelial damage in patients on hemodialysis and hemodiafiltration.
Małyszko JS; Małyszko J; Hryszko T; Koźminski P; Pawlak K; Mysliwiec M
J Nephrol; 2006; 19(2):150-4. PubMed ID: 16736412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
